Adly 1992.

Methods	Single‐centre, double‐blind, randomised, parallel study: fluoxetine versus placebo No control for symptomatic/analgesic medications use
Participants	Country: USA N = 32 participants Sex: 3 M, 15 F (sex not reported for drop‐outs) Mean age: fluoxetine 34, placebo 41 Diagnosis: migraine according to Ad hoc Committee on Classification of Headache (Ad Hoc 1962) Exclusion criteria: less then 1 weekly severe disabling migraine headache, concomitant medical conditions, overuse of alcohol and drugs Recruitment: volunteers solicited through a local newspaper and paid to participate (USD 40)
Interventions	N = 16 fluoxetine to a maximum of 40 mg/day N = 16 placebo Active treatment: 8 weeks
Outcomes	1. Migraine Headache Score = intensity (scale 1 to 10) * duration * amount of medications used to abort attacks 2. Zung Depression Rating Scale
Notes	14 drop‐outs (44%): Fluoxetine: 7 (4 did not keep appointments, 2 for lack of efficacy,1 for side effects) Placebo: 7 (2 lack of efficacy, 4 changed their mind, 1 submitted an incomplete diary) Per protocol analysis No sample size calculation
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information
Allocation concealment (selection bias)	Unclear risk	Prescription for fluoxetine or placebo to be filled by the hospital pharmacy
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No information
Incomplete outcome data (attrition bias) All outcomes	High risk	High drop‐out rate (44%)
Selective reporting (reporting bias)	Unclear risk	No information
Other bias	Unclear risk	Financial support not reported